PT  - JOURNAL ARTICLE
AU  - Koopman, James S.
AU  - Simon, Carl P.
AU  - Getz, Wayne M.
AU  - Salter, Richard
TI  - Modeling the population effects of epitope specific escape mutations in SARS-CoV-2 to guide vaccination strategies
AID  - 10.1101/2021.01.19.21250114
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.19.21250114
4099  - http://medrxiv.org/content/early/2021/01/20/2021.01.19.21250114.short
4100  - http://medrxiv.org/content/early/2021/01/20/2021.01.19.21250114.full
AB  - Escape mutations (EM) to SARS-Cov-2 have been detected and are spreading. Vaccines may need adjustment to respond to these or future mutations. We designed a population level model integrating both waning immunity and EM. We also designed a set of criteria for elaborating and fitting this model to cross-neutralization and other data in a manner that minimizes vaccine decision errors. We formulated four model variations. These define criteria for which prior infections provide immunity that can be escaped. They also specify different sequences where one EM follows another. At all reasonable parameter values, these model variations led to patterns where: 1) EM were rare in the first epidemic, 2) rebound epidemics after the first epidemic were accelerated more by increasing drifting than by increasing waning (with some exceptions), 3) the long term endemic level of infection was determined mostly by waning rates with small effects of the drifting parameter, 4) EM caused loss of vaccine effectiveness and under some conditions, vaccines induced EM that caused higher levels of infection with vaccines than without them. The differences and similarities across the four models suggest paths for developing models specifying the epitopes where EM act. This model is a base on which to construct epitope specific evolutionary models using new high-throughput assay data from population samples to guide vaccine decisions.HighlightsThis model is the first to integrate both antigenic drifting from escape mutations and immunity waning in continuous time.Tiny amounts of only waning or only escape mutation drifting have small or no effects. Together, they have large effects.There are no or few escape mutations during the first epidemic peak and no effect of drifting parameters on the size of that wave.After the first epidemic peak, escape mutations accumulate rapidly. They increase with increases in waning rates and with increases in the drifting rate. Escape mutations then amplify other escape mutations since these raise the frequency of reinfections.Escape mutations can completely negate the effects of vaccines and even lead to more infections with vaccination than without, especially at very low waning rates.The model generates population level cross-neutralization patterns that enable the model to be fitted to population level serological data.The model can be modified to use laboratory data that determine the epitope specific effects of mutations on ACE2 attachment strength or escape from antibody effects.The model, although currently unable to predict the effects of escape mutations in the real world, opens up a path that can guide model incorporation of molecularly studied escape mutations and improve predictive value. We describe that path.Model analysis indicates that vaccine trials and serological surveys are needed now to detect the effects of epitope specific escape mutations that could cause the loss of vaccine efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis was done by emeritus professors with no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was purely a modeling study with no human data being usedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no data in this paper. It is purely a modeling study.